Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 3Phase 1 3Phase NA 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 1Castrate Sensitive Prostate Cancer 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × abiraterone × 30 days × Clear all
NCT03934840 2026-05-26

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
61 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
28 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡